


Kindly amend the application as follows:

IN THE CLAIMS

Cancel claims 1-11, 14 and 15.

Amend claim 12 as follows\*:

B1  
12. (Twice Amended) A pharmaceutical composition comprising a D- or L-tryptophanyl-ester or its N-acyl derivative for the prophylaxis and/or therapy of oxidative pathologic processes in degenerative and/or cancer diseases having the following formula:




wherein X is  $C(O)R_1$  or H, and  $R_1$  is a saturated C2-C18 carbon hydrogen residue and  $R_2$  is a saturated or unsaturated C2-C18 carbon hydrogen residue, and a pharmaceutically acceptable carrier, alone or in combination with a second therapeutic compound.

Add claims 18-28.

B2  
18. (Added) A pharmaceutical composition comprising a D- or L-tryptophanyl-ester or its N-acyl derivative, wherein the D- or L-tryptophanyl-ester or its N-acyl derivative has the following formula:

\* An Appendix showing changes made to claim 12 is attached hereto. Deletions are indicated by brackets and additions are underlined.



wherein X is C(O)R<sub>1</sub> or H, and R<sub>1</sub> is a saturated C<sub>2</sub>-C<sub>18</sub> or unsaturated C<sub>2</sub>-C<sub>7</sub> carbon hydrogen residue and R<sub>2</sub> is a saturated or unsaturated C<sub>9</sub>-C<sub>18</sub> carbon hydrogen residue and a pharmaceutically acceptable carrier.

19. (Added) The pharmaceutical composition according to claim 18, wherein the D- or L-tryptophanyl-ester or its N-acyl derivative is selected from the group consisting of tryptophanstearyl-ester, tryptophanpalmityl-ester, tryptophanoleyl-ester, N-acetyl-tryptophandodecyl-ester, N-acetyl-tryptophanstearyl-ester, N-acetyl-tryptophanpalmityl-ester, N-acetyl-tryptophanoleyl-ester, N-dodecanoyl-tryptophanoctyl-ester, N-dodecanoyl-tryptophandodecyl-ester, N-dodecanoyl-tryptophanstearyl-ester, N-dodecanoyl-tryptophanpalmityl-ester, N-dodecanoyl-tryptophanoleyl-ester, N-hexoyl-tryptophanethyl-ester, N-octoyl-tryptophanethyl-ester, N-dodecanoyl-tryptophanethyl-ester, N-stearoyl-tryptophanethyl-ester and N-palmitoyl-tryptophanethyl-ester.

20. (Added) The pharmaceutical composition according to claim 18, wherein the D- or L-tryptophanethyl-ester or its N-acetyl derivative is N-dodecanoyl-tryptophanethyl-ester.

21. (Added) The pharmaceutical composition according to claim 18, further comprising a second therapeutic compound.

22. (Added) The pharmaceutical composition according to claim 12 or 21, wherein the second therapeutic compound is for treating a degenerative disease or cancer.

23. (Added) The pharmaceutical composition according to claim 12 or 21, wherein the second therapeutic compound is selected from the group consisting of ciliary neurotropic factor (CNTF), aniracetam, buflomedil, choline, co-dergocrine, cyclandelate, desferrioxamine, eptastigmine, fampridine, galantamine, isoxusuprine, lecithin, linopiridine, metriphonate, naffidrofuryl, nicergoline, nicotine, nimodipine, oxiracetam, physostigmine, pilocarpine, piracetam, pramiracetam, propentofylline, pyritinol, RS-86, selegiline, suronacrine, tacrine, velnacrine, somatomedines, protirelin, an immunoglobulin and an immunosuppressiva.

24. (Added) The composition according to claim 21, wherein the degenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, apoplectic fit and amyotrophic lateral sclerosis.

25. (Added) The composition according to claim 21, wherein the degenerative disease is Alzheimer's disease.

26. (Added) The composition according to claim 21, wherein the degenerative disease is Parkinson's disease.

27. (Added) The composition according to claim 21, wherein the degenerative disease is apoplectic fit.

28. (Added) The composition according to claim 21, wherein the degenerative disease is amyotrophic lateral sclerosis.